Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1).
Daudén E, de la Cueva P, Salgado-Boquete L, Llamas-Velasco M, Fonseca E, Pau-Charles I, Asensio D, Guilà M, Carrascosa JM; DIMESKIN 1 Study investigators. Daudén E, et al. Among authors: pau charles i. Dermatol Ther (Heidelb). 2023 Jan;13(1):329-345. doi: 10.1007/s13555-022-00863-2. Epub 2022 Dec 1. Dermatol Ther (Heidelb). 2023. PMID: 36456890 Free PMC article.
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
Fernandez AP, Dauden E, Gerdes S, Lebwohl MG, Menter MA, Leonardi CL, Gooderham M, Gebauer K, Tada Y, Lacour JP, Bianchi L, Egeberg A, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Mehta NN. Fernandez AP, et al. Among authors: pau charles i. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1774-1783. doi: 10.1111/jdv.18167. Epub 2022 Jun 25. J Eur Acad Dermatol Venereol. 2022. PMID: 35460287 Free PMC article. Clinical Trial.
Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials.
Thaçi D, Jullien D, Egeberg A, Carrascosa JM, Wu JJ, Pau-Charles I, Gisondi P. Thaçi D, et al. Among authors: pau charles i. J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e709-e711. doi: 10.1111/jdv.17427. Epub 2021 Jul 14. J Eur Acad Dermatol Venereol. 2021. PMID: 34058035 Clinical Trial. No abstract available.
Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020.
Mrowietz U, Van De Kerkhof P, Schoenenberger A, Ryzhkova A, Pau-Charles I, Llamas-Velasco M, Daudén E, Carrascosa JM, Cueva P, Salgado-Boquete L, Guilà M, Fernández-Soriano FJ, Augustin M, Loew-Juettner C, Kirsch A, Diemert S, Hadshiew I. Mrowietz U, et al. Among authors: pau charles i. Expert Rev Clin Immunol. 2021 May;17(sup2):1-11. doi: 10.1080/1744666X.2021.1919510. Epub 2021 May 17. Expert Rev Clin Immunol. 2021. PMID: 33899642
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, Foley P, Igarashi A, Langley RG, Asahina A, Young M, Falqués M, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Reich K. Thaci D, et al. Among authors: pau charles i. Br J Dermatol. 2021 Aug;185(2):323-334. doi: 10.1111/bjd.19866. Epub 2021 May 4. Br J Dermatol. 2021. PMID: 33544883 Clinical Trial.
Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.
van de Kerkhof PCM, Loewe R, Mrowietz U, Falques M, Pau-Charles I, Szepietowski JC. van de Kerkhof PCM, et al. Among authors: pau charles i. J Eur Acad Dermatol Venereol. 2020 Jan;34(1):119-126. doi: 10.1111/jdv.15922. Epub 2019 Oct 17. J Eur Acad Dermatol Venereol. 2020. PMID: 31465585 Free PMC article. Clinical Trial.
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, Ohtsuki M, Falqués M, Harmut M, Rozzo S, Lebwohl MG, Cantrell W, Blauvelt A, Thaçi D. Reich K, et al. Among authors: pau charles i. Br J Dermatol. 2020 Mar;182(3):605-617. doi: 10.1111/bjd.18232. Epub 2019 Jul 18. Br J Dermatol. 2020. PMID: 31218661 Free PMC article.
21 results